Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 1

Status

Terminated 3Unknown 2

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Other solid neoplasm 5Breast 5Gastrointestinal 4Genitourinary 2Dermatologic 1

Conditions

Breast Neoplasms 5Neoplasm Metastasis 3Triple Negative Breast Neoplasms 1

Interventions

Trastuzumab 242Paclitaxel 223Fulvestrant 196Capecitabine 182Docetaxel 164Letrozole 142pembrolizumab 115Carboplatin 100exemestane 98Gemcitabine 98Cyclophosphamide 92palbociclib 86Anastrozole 83pertuzumab 78Lapatinib 73Bevacizumab 71ribociclib 68130-nm albumin-bound paclitaxel 66abemaciclib 59eribulin 58Doxorubicin 55Vinorelbine 51Injections 47Ado-Trastuzumab Emtansine 47Tamoxifen 45Everolimus 44Albumin-Bound Paclitaxel 44atezolizumab 35trastuzumab deruxtecan 34Nivolumab 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × tesetaxel × Breast × Clear all
NCT03326674 2021-07-30

CONTESSA

Odonate Therapeutics, Inc.

Phase 3 Terminated
685 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT03858972 2021-07-30

CONTESSA 2

Odonate Therapeutics, Inc.

Phase 2 Terminated
152 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT03952325 2021-07-30

CONTESSA TRIO

Odonate Therapeutics, Inc.

Phase 2 Terminated
294 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT01221870 2012-07-24

Tesetaxel as First-line Therapy for Metastatic Breast Cancer

Genta Incorporated

Phase 2 Unknown
81 enrolled
Breast

Breast Neoplasms

NCT01609127 2012-06-01

Tesetaxel Every 3 Weeks vs Weekly vs Capecitabine as 1st-line Therapy for Locally Advanced or Metastatic Breast Cancer

Genta Incorporated

Phase 2 Unknown
213 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡